Press Release

May 05, 2022
1 min read

FDA expands Enhertu approval for breast cancer


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA expanded the approval of fam-trastuzumab deruxtecan to include treatment of patients with HER2-positive metastatic breast cancer who received a prior anti-HER2-based regimen.

Fam-trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a novel antibody-drug conjugate with three components: a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino acid sequence as trastuzumab (Herceptin, Genentech); a topoisomerase 1 inhibitor payload; and a tetrapeptide-based cleavable linker.

Study response rates.
Data derived from Cortés S, et al. N Engl J Med. 2022;doi:10.1056/NEJMoa2115022.

The agent already had been approved in the United States for treatment of adults with unresectable or metastatic HER2-positive breast cancer who had received two or more prior anti-HER2-based regimens, as well as for treatment of adults with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who received a prior trastuzumab-based regimen.

The FDA based the new breast cancer indication on results of the randomized phase 3 DESTINY-Breast03 trial, which enrolled approximately 500 patients from North America, South America, Europe, Asia and Oceania. All patients had HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

Researchers compared fam-trastuzumab deruxtecan — dosed at 5.4 mg/kg — vs. the HER2-targeted antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla, Genentech).

PFS assessed by blinded independent central review served as the primary efficacy endpoint.

As Healio previously reported, results showed fam-trastuzumab deruxtecan reduced risk for progression or death by 72% compared with ado-trastuzumab emtansine (HR = 0.28; 95% CI, 0.22-0.37).

Fam-trastuzumab deruxtecan exhibited a safety profile consistent with that observed in prior clinical trials. No grade 4 or grade 5 treatment-related interstitial lung disease events occurred.

“Enhertu has demonstrated significant progression-free survival in the earlier metastatic setting, potentially establishing it as a new standard of care in previously treated patients with HER2-positive metastatic breast cancer,” Erika Hamilton, MD, director of the breast cancer and gynecologic cancer research program at Sarah Cannon Research Institute, said in an AstraZeneca-issued press release. “[This] approval is an important milestone for the clinical community as we will now be able to offer Enhertu to these patients earlier in their treatment.”